ES2061642T3 - Metodo para la purificacion del factor viii:c de una mezcla de polipeptidos y otros constituyentes. - Google Patents

Metodo para la purificacion del factor viii:c de una mezcla de polipeptidos y otros constituyentes.

Info

Publication number
ES2061642T3
ES2061642T3 ES88302905T ES88302905T ES2061642T3 ES 2061642 T3 ES2061642 T3 ES 2061642T3 ES 88302905 T ES88302905 T ES 88302905T ES 88302905 T ES88302905 T ES 88302905T ES 2061642 T3 ES2061642 T3 ES 2061642T3
Authority
ES
Spain
Prior art keywords
polypeptide
polypeptides
constituents
purification
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88302905T
Other languages
English (en)
Inventor
Michael J Griffith
Gerald Neslund
Shu-Len Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26708905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2061642(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter International Inc filed Critical Baxter International Inc
Application granted granted Critical
Publication of ES2061642T3 publication Critical patent/ES2061642T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTA UN PROCEDIMIENTO PARAPURIFICAR POLIPEPTIDOS QUE CONSISTE EN PONER EN CONTACTO UN ANTICUERPO INMOVILIZADO, LIGANTE ESPECIFICO DE UN POLIPEPTIDO, CON DICHO POLIPEPTIDO, DESADSORBER EL POLIPEPTIDO DEL ANTICUERPO QUE LO HA ADSORBIDO, ELUIR EL POLIPEPTIDO DE LA PRESENCIA DEL ANTIGENO, PASAR EL POLIPEPTIDO ELUIDO A TRAVES DE UNA REGION DE AFINIDAD CAPAZ DE LIGAR A DICHO POLIPEPTIDO, LIGAR AL POLIPEPTIDO EN LA REGION DE AFINIDAD Y PASAR LOS CONTAMINANTES A TRAVES DE DICHA REGION Y, FINALMENTE. ELUIR EL POLIPEPTIDO PURIFICADO.
ES88302905T 1987-03-31 1988-03-31 Metodo para la purificacion del factor viii:c de una mezcla de polipeptidos y otros constituyentes. Expired - Lifetime ES2061642T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3280087A 1987-03-31 1987-03-31
US16790288A 1988-03-28 1988-03-28

Publications (1)

Publication Number Publication Date
ES2061642T3 true ES2061642T3 (es) 1994-12-16

Family

ID=26708905

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88302905T Expired - Lifetime ES2061642T3 (es) 1987-03-31 1988-03-31 Metodo para la purificacion del factor viii:c de una mezcla de polipeptidos y otros constituyentes.

Country Status (7)

Country Link
US (1) US5470954C1 (es)
EP (1) EP0286323B1 (es)
JP (1) JP2686766B2 (es)
CA (1) CA1339946C (es)
DE (1) DE3886249T2 (es)
DK (1) DK174968B1 (es)
ES (1) ES2061642T3 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047717C (en) * 1989-03-14 2000-08-01 Fred W. Wagner Monoclonal antibodies for small moieties, methods therefor
US5639624A (en) * 1989-03-14 1997-06-17 Board Of Regents Of The University Of Nebraska Monoclonal antibodies specific for metallic cations and method therefor
JPH0327109A (ja) * 1989-06-24 1991-02-05 Hagiwara Kogyo Kk 生物分解性フラットヤーンの製造方法
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
AT402153B (de) * 1989-06-26 1997-02-25 Immuno Ag Protein-s-hältige pharmazeutische präparation
JPH0427865A (ja) * 1989-12-21 1992-01-30 Kurita Water Ind Ltd 血液凝固因子用分離剤およびその製造方法
FR2662166A1 (fr) * 1990-05-18 1991-11-22 Fondation Nale Transfusion San Procede de preparation de facteur viii de tres haute purete comprenant une etape rapide d'immunoadsorption.
HUT72191A (en) 1993-01-29 1996-03-28 Dahlbaeck Novel anticoagulant cofactor activity
DE4337573C1 (de) * 1993-11-04 1995-05-18 Octapharma Ag Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
US6111079A (en) * 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
DK0998486T4 (da) 1997-06-13 2012-05-14 Genentech Inc Proteinoprensning ved kromatografi efterfulgt af filtrering på en ladet fase
US7820796B2 (en) * 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
ATE222925T1 (de) * 1998-03-12 2002-09-15 Inst Genetics Llc Verbessertes verfahren zur herstellung von faktor viii
DE69936946T2 (de) * 1998-05-06 2008-05-15 Genentech, Inc., South San Francisco Reinigung von Antikörpern durch Ionenaustauschchromatographie
US6855509B2 (en) 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
PT1835938E (pt) 2004-12-27 2013-11-06 Baxter Int Conjugados de polímero-factor de von willebrand
CN1302009C (zh) * 2005-09-05 2007-02-28 武汉海特生物制药股份有限公司 用有机溶剂病毒灭活法制备鼠神经生长因子的工艺
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
KR100791502B1 (ko) 2006-09-29 2008-01-03 한스바이오메드 주식회사 바이러스 불활화된 무세포 인체 이식재 생산방법
BRPI0821599A2 (pt) * 2007-12-28 2015-06-16 Baxter Int Método de filtração de uma mistura líquida de proteína
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
AU2011301803A1 (en) * 2010-09-17 2013-03-21 Baxalta GmbH Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral pH
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
AU2012324020A1 (en) * 2011-12-30 2013-07-18 Grifols, S.A. Method for purifying Factor VIII
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US20160130361A1 (en) * 2013-06-13 2016-05-12 Biogen Ma Inc. Anti-factor viii antibodies or uses thereof
CN110167594B (zh) 2017-01-17 2023-11-21 豪夫迈·罗氏有限公司 皮下her2抗体配制剂
KR20230144110A (ko) 2017-03-02 2023-10-13 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962421A (en) * 1973-06-18 1976-06-08 American Home Products Corporation Method for the disruption of lipid-containing viruses
US4086218A (en) * 1975-04-11 1978-04-25 Edward Shanbrom, Inc. Method of preserving blood plasma II
US4188318A (en) * 1975-06-16 1980-02-12 Edward Shanbrom Simplified method for preparation of high yield, high purity Factor VIII concentrate
DE2550011C2 (de) * 1975-11-07 1982-11-25 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines antihämophilen Mittels
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4412985A (en) * 1980-10-06 1983-11-01 Edward Shanbrom Depyrogenation process
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
ATE14269T1 (de) * 1981-02-26 1985-08-15 Unilever Nv Verfahren und vorrichtung zur rueckgewinnung von immunoglobulinen.
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4591505A (en) * 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4511556A (en) * 1982-06-10 1985-04-16 The United States Of America As Represented By The Department Of Health And Human Services Inactivation of a lipid virus
US4581231A (en) * 1982-06-10 1986-04-08 The United States Of America As Represented By The Secretary Of Health And Human Services Inactivation of viruses containing essential lipids
US4485017A (en) * 1982-12-22 1984-11-27 Cetus Corporation Isolation of human interferon by immunosorbent and high performance liquid chromatography
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
IE80858B1 (en) * 1983-03-31 1999-04-21 Scripps Research Inst New factor viii coagulant polypeptides
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
US5214033A (en) * 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
WO1985001941A1 (en) * 1983-10-28 1985-05-09 New England Medical Center Hospitals, Inc. Method for the purification and isolation of blood clotting proteins using conformation specific antibodies
EP0150735B2 (en) * 1984-01-12 2004-01-07 Chiron Corporation Protein composition exhibiting coagulation activity and method for the preparation thereof
US4578335A (en) * 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
WO1986000910A1 (en) * 1984-07-30 1986-02-13 Celltech Limited Immunopurification process
JPS6151000A (ja) * 1984-08-17 1986-03-13 Toray Ind Inc ヒト・インタ−フエロンβの精製法
DE3432083A1 (de) * 1984-08-31 1986-03-06 Behringwerke Ag, 3550 Marburg Pasteurisierte, isoagglutininfreie faktor viii-praeparation und verfahren zu ihrer herstellung
JPS61145200A (ja) * 1984-12-19 1986-07-02 Snow Brand Milk Prod Co Ltd ウシラクトフェリンの分離精製法
US4613501A (en) * 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
JPS61242593A (ja) * 1985-04-19 1986-10-28 Toray Ind Inc ヒト・インタ−フエロンβの精製法
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
US4740306A (en) * 1986-03-17 1988-04-26 Temple University - Of The Commonwealth System Of Higher Education Chromatographic column
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
US4765903A (en) * 1987-10-06 1988-08-23 Interferon Sciences, Inc. Purification of monomeric interferon

Also Published As

Publication number Publication date
JP2686766B2 (ja) 1997-12-08
US5470954C1 (en) 2001-02-06
EP0286323A2 (en) 1988-10-12
DK184088D0 (da) 1988-04-05
DK174968B1 (da) 2004-04-05
DE3886249T2 (de) 1994-06-30
EP0286323B1 (en) 1993-12-15
DK184088A (da) 1988-10-01
EP0286323A3 (en) 1988-11-17
DE3886249D1 (de) 1994-01-27
US5470954A (en) 1995-11-28
CA1339946C (en) 1998-07-07
JPS6413099A (en) 1989-01-17

Similar Documents

Publication Publication Date Title
ES2061642T3 (es) Metodo para la purificacion del factor viii:c de una mezcla de polipeptidos y otros constituyentes.
ES2075196T3 (es) Metodo para el uso y la sintesis de peptidos.
ES2155477T3 (es) Purificacion cromatografica y procedimiento de separacion de acidos nucleicos.
ES8302311A1 (es) Metodo para la determinacion de un analito biologico de interes utilizando agentes pluorescentes encapsulados.
IT8722030A0 (it) Procedimento di frazionamento di miscele gassose idrocarburiche ad alto contenuto di gas acidi.
DK0425066T3 (da) Krystallinsk 2-O-alpha-D-glucopyranosyl-L-ascorbinsyre og fremstilling heraf og anvendelser herfor
ATE114172T1 (de) Reinigungsverfahren für antikörper.
ES8506902A1 (es) Un procedimiento para la purificacion de un antigeno.
FI864427A (fi) Menetelmä polypeptidin valmistamiseksi, joka on komplementaarinen ainakin osalle alkuperäistä peptidiä tai proteiinia, ja komplementaarisen polypeptidin käyttö
DK732988A (da) Fremgangsmaade til genteknologisk fremstilling af antistoffer
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
EP0208215A3 (en) Purification of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
DE3882797T2 (de) Schwach affinitives Adsorbens für Affinitätschromatographie.
ES2058272T3 (es) Fluoxetina util para el tratamiento de la diabetes.
ES8407499A1 (es) Un metodo para la obtencion de interferon inmune humano homogeneo de pureza aumentada.
ES2100960T3 (es) Estructura proteica de la toxina vegetal gelonina.
EP0268296A3 (en) Membrane affinity concentration immunoassay
ATE109834T1 (de) Monoklonaler antikörper spezifisch gegen humane pankreas-phospholipase-a2.
ES2041690T3 (es) Metodo para la purificacion de anticuerpos.
SE9201976D0 (sv) En metod foer att adsorbera proteiner och peptider till hydrofoba zeoliter
ES2019598B3 (es) Metodo para evitar la desodorizacion del gas de petroleo licuado odorizado con compuestos de organoazufre.
FI861321A0 (fi) Foerfaranden foer stabilisering av prostatspecifik antigen i naturella matriser.
ATE110853T1 (de) Immuntestverfahren für zelluläres eiweiss.
ATE3156T1 (de) Apoglucoseoxydase-zusammensetzung und ihre herstellung.
ES2145466T3 (es) Procedimiento para la purificacion del factor viii por cromatografia de afinidad.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 286323

Country of ref document: ES